Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimeric Antigen Receptor T-cell”

828 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 828 results

Early research (Phase 1)Looking for participantsNCT07295847
What this trial is testing

AZD0120 in Autoimmune Diseases

Who this might be right for
Systemic SclerosisIdiopathic Inflammatory MyopathiesRheumatoid Arthritis
AstraZeneca 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT03642626
What this trial is testing

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaLarge B-cell Lymphoma
Masonic Cancer Center, University of Minnesota 150
Early research (Phase 1)Temporarily pausedNCT03710421
What this trial is testing

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
City of Hope Medical Center 30
Testing effectiveness (Phase 2)Looking for participantsNCT06897930
What this trial is testing

Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Who this might be right for
Lupus Erythematosus, Systemic
AstraZeneca 150
Early research (Phase 1)Study completedNCT04240808
What this trial is testing

Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Who this might be right for
Non Hodgkin Lymphoma
University of Colorado, Denver 10
Very early researchUnknownNCT05085418
What this trial is testing

CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

Who this might be right for
Immune NephritisAutoimmune DiseasesLupus Nephritis
Zhejiang University 9
Testing effectiveness (Phase 2)Looking for participantsNCT06794008
What this trial is testing

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Who this might be right for
Systemic Lupus ErythematosusInflammatory MyopathySystemic Sclerosis (SSc)+6 more
Peking University People's Hospital 50
Early research (Phase 1)Looking for participantsNCT05210907
What this trial is testing

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Seoul National University Hospital 5
Early research (Phase 1)Study completedNCT00019136
What this trial is testing

Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer

Who this might be right for
Ovarian Cancer
National Cancer Institute (NCI)
Early research (Phase 1)UnknownNCT05528887
What this trial is testing

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Who this might be right for
Relapsed/Refractory Hematological MalignanciesLymphomaMyeloma+1 more
The Affiliated People's Hospital of Ningbo University 10
Very early researchUnknownNCT04186052
What this trial is testing

Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)UnknownNCT03262298
What this trial is testing

Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies

Who this might be right for
LeukemiaLymphoma
Affiliated Hospital to Academy of Military Medical Sciences 20
Testing effectiveness (Phase 2)Ended earlyNCT03954106
What this trial is testing

A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity

Who this might be right for
DLBCLNeurotoxicity Syndromes
Jazz Pharmaceuticals 25
Testing effectiveness (Phase 2)WithdrawnNCT02723942
What this trial is testing

CAR-T Cell Immunotherapy for HCC Targeting GPC3

Who this might be right for
GPC3 Positive Hepatocellular CarcinomaCAR-T Cell Immunotherapy
Fuda Cancer Hospital, Guangzhou
Testing effectiveness (Phase 2)Active Not RecruitingNCT06665256
What this trial is testing

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

Who this might be right for
Idiopathic Inflammatory Myopathies
Novartis Pharmaceuticals 21
Testing effectiveness (Phase 2)Looking for participantsNCT06316856
What this trial is testing

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

Who this might be right for
T-Cell Acute Lymphocytic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia+1 more
Beijing GoBroad Hospital 54
Early research (Phase 1)Active Not RecruitingNCT03085173
What this trial is testing

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)RelapsedRefractory
Memorial Sloan Kettering Cancer Center 39
Early research (Phase 1)Looking for participantsNCT06198296
What this trial is testing

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Who this might be right for
HepatoblastomaHepatocellular CarcinomaWilms Tumor+5 more
Baylor College of Medicine 21
Testing effectiveness (Phase 2)UnknownNCT04272151
What this trial is testing

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma Cell
Chongqing Precision Biotech Co., Ltd 40
Testing effectiveness (Phase 2)Looking for participantsNCT04276870
What this trial is testing

Orphan Indications for CD19 Redirected Autologous T Cells

Who this might be right for
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Stephan Grupp MD PhD 133
Load More Results